{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:44:05Z","timestamp":1785887045901,"version":"3.56.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016986","name":"Nippon Zenyaku Kogyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016986","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.transproceed.2026.05.014","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T03:50:07Z","timestamp":1781149807000},"page":"1104-1113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Real-World Safety and Effectiveness of Rituximab in Preventing Antibody-Mediated Rejection in ABO-Incompatible Liver Transplantation: All-Case Postmarketing Surveillance in Japan"],"prefix":"10.1016","volume":"58","author":[{"given":"Mana","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7287-635X","authenticated-orcid":false,"given":"Takashi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.transproceed.2026.05.014_bib0001","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1744-313X.2012.01101.x","article-title":"ABO-incompatible organ transplantation","volume":"39","author":"Subramanian","year":"2012","journal-title":"Int J Immunogenet"},{"issue":"9","key":"10.1016\/j.transproceed.2026.05.014_bib0002","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/hepr.13364","article-title":"Liver transplantation in Japan: registry by the Japanese Liver Transplantation Society","volume":"49","author":"Umeshita","year":"2019","journal-title":"Hepatol Res"},{"key":"10.1016\/j.transproceed.2026.05.014_bib0003","unstructured":"The Japan Society for Transplantaion. Ethics guidelines.https:\/\/www.asas.or.jp\/jst\/about\/doc\/info_20210918_1.pdf?20240124 [accessed 20.08.25]."},{"key":"10.1016\/j.transproceed.2026.05.014_bib0004","unstructured":"Japanese Society for Clinical Renal Transplantation and the Japan Society for Transplantation. Annual progress report from the Japanese renal transplant registry: number of renal transplantations in 2021 and follow-up survey. https:\/\/www.jstage.jst.go.jp\/article\/jst\/57\/3\/57_199\/_pdf\/-char\/ja [accessed 20.08.25]."},{"issue":"3","key":"10.1016\/j.transproceed.2026.05.014_bib0005","first-page":"221","article-title":"Liver transplantation in Japan\u2014registry by the Japanese Liver Transplantation Society","volume":"57","author":"The Japanese Liver Transplantation Society","year":"2022","journal-title":"Ishoku"},{"issue":"4","key":"10.1016\/j.transproceed.2026.05.014_bib0006","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.hbpd.2020.06.017","article-title":"Challenge to ABO blood type barrier in living donor liver transplantation","volume":"19","author":"Egawa","year":"2020","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"4","key":"10.1016\/j.transproceed.2026.05.014_bib0007","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/ajt.12667","article-title":"The role of donor-specific HLA alloantibodies in liver transplantation","volume":"14","author":"O\u2019Leary","year":"2014","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.transproceed.2026.05.014_bib0008","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/MOT.0b013e328353584c","article-title":"Antibody-mediated rejection in the liver allograft","volume":"17","author":"H\u00fcbscher","year":"2012","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.transproceed.2026.05.014_bib0009","unstructured":"Zenyaku Kogyo Co., Ltd. Rituxan intravenous infusion: interview form. 2024. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/4291407 [accessed 20.08.25]."},{"key":"10.1016\/j.transproceed.2026.05.014_bib0010","unstructured":"Zenyaku Kogyo Co., Ltd. Rituxan intravenous infusion package insert. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/4291407 [accessed 20.08.25]."},{"key":"10.1016\/j.transproceed.2026.05.014_bib0011","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fonc.2018.00163","article-title":"Past, present, and future of rituximab\u2014the world\u2019s first oncology monoclonal antibody therapy","volume":"8","author":"Pierpont","year":"2018","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.transproceed.2026.05.014_bib0012","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/ajt.12220","article-title":"A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function","volume":"13","author":"Kamburova","year":"2013","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.transproceed.2026.05.014_bib0013","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/ajt.12520","article-title":"Impact of rituximab desensitization on blood-type-incompatible adult living donor liver transplantation: a Japanese multicenter study","volume":"14","author":"Egawa","year":"2014","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.transproceed.2026.05.014_bib0014","doi-asserted-by":"crossref","first-page":"126","DOI":"10.21037\/tau.2019.03.05","article-title":"Current protocols and outcomes of ABO-incompatible kidney transplantation based on a single-center experience","volume":"8","author":"Okumi","year":"2019","journal-title":"Transl Androl Urol"},{"issue":"4","key":"10.1016\/j.transproceed.2026.05.014_bib0015","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s10157-016-1321-5","article-title":"Results of a multicenter prospective clinical study in Japan for evaluating efficacy and safety of desensitization protocol based on rituximab in ABO-incompatible kidney transplantation","volume":"21","author":"Takahashi","year":"2017","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"10.1016\/j.transproceed.2026.05.014_bib0016","first-page":"062","article-title":"Retrospective report of safety and efficacy of rituximab in ABO incompatible living donor liver transplantation","volume":"50","author":"Egawa","year":"2015","journal-title":"Ishoku"},{"issue":"2","key":"10.1016\/j.transproceed.2026.05.014_bib0017","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/TP.0000000000004250","article-title":"Current status of ABO-incompatible liver transplantation","volume":"107","author":"Egawa","year":"2023","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2026.05.014_bib0018","unstructured":"Zenyaku Kogyo Co., Ltd. Risk management plan for rituxan intravenous infusion. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/4291407 [accessed 20.08.25]."},{"issue":"8","key":"10.1016\/j.transproceed.2026.05.014_bib0019","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000001180","article-title":"Rituximab desensitization in liver transplant recipients with preformed donor-specific HLA Antibodies: a Japanese nationwide survey","volume":"7","author":"Akamatsu","year":"2021","journal-title":"Transplantation Direct"},{"issue":"7","key":"10.1016\/j.transproceed.2026.05.014_bib0020","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1097\/TP.0000000000005374","article-title":"The fourth international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"109","author":"Kotton","year":"2025","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.transproceed.2026.05.014_bib0021","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/cld.883","article-title":"Reactivation of hepatitis B virus: a review of clinical guidelines","volume":"15","author":"Myint","year":"2020","journal-title":"Clin Liver Dis"},{"issue":"4","key":"10.1016\/j.transproceed.2026.05.014_bib0022","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","article-title":"Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab","volume":"27","author":"Yeo","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134526002770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134526002770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:47:10Z","timestamp":1785883630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134526002770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0041134526002770"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2026.05.014","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Real-World Safety and Effectiveness of Rituximab in Preventing Antibody-Mediated Rejection in ABO-Incompatible Liver Transplantation: All-Case Postmarketing Surveillance in Japan","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2026.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}